Test Price
750 AED✅ Home Collection Available
ROMA (Risk of Ovarian Malignancy Algorithm) Test in UAE | 750 AED | DHA Licensed Lab
Executive Summary & Core Metrics
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited laboratory processing (Cert: INT/EGQ/2509DA/3139). Dual-marker chemiluminescent immunoassay with menopausal status integration.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. This ensures sample integrity from your doorstep to our DHA-licensed facility (License: 1143).
Clinical Guidance: Complimentary telephonic post-test consultation with our specialist team to interpret ROMA results in the context of your imaging and clinical history.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We handle individual and corporate plans with full transparency under UAE PDPL.
Test Overview & Methodology
The ROMA algorithm integrates serum CA125, HE4, and menopausal status to compute a personalized risk score for ovarian malignancy in women with an adnexal mass. This evidence-based stratification supports timely referral to gynecologic oncology and reduces unnecessary surgeries.
| Parameter | Our ROMA Test | Standalone CA125 / HE4 Tests |
|---|---|---|
| Precision | Algorithmic combination with menopausal status; superior sensitivity & specificity | Single marker; reduced accuracy, especially in premenopausal patients |
| Methodology | Chemiluminescent Microparticle Immunoassay (CMIA) – automated, high‑throughput | Often ECLIA or ELISA; manual interpretation may vary |
| Turnaround Time | Same day (sample collection Mon/Thu before 4 PM) | 2–3 days typical |
| Pre‑analytical Guidance | Menopausal status mandatory; cold‑chain logistics included | Often no structured pre‑test counseling |
Physician Insight & Safety Protocols
“As a radiologist specializing in oncologic imaging, I routinely see the value of integrated tumor markers. The ROMA score provides a statistically robust risk layer, but it must be interpreted within the full clinical and radiological context of the patient's presentation. It is a powerful guide for the next diagnostic step, not a standalone diagnosis.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory: Medication & Clinical Context
Medication Advisory: Do not discontinue or alter any prescribed medication based on this test result alone. The ROMA score is a risk stratification tool, not a standalone diagnostic or therapeutic directive. Any changes to your treatment plan must be supervised by your treating physician.
Exclusion Criteria & Emergency Red Flags
- Pregnancy or postpartum state (CA125 and HE4 levels are physiologically altered).
- Acute pelvic inflammatory disease or active endometriosis (may cause false‑positive elevations).
- Known benign ovarian cysts with classical ultrasound features (unless malignancy is suspected).
- Seek emergency care if you experience: sudden, severe abdominal‑pelvic pain, fever, vomiting, or signs of ovarian torsion — these require immediate medical attention and are unrelated to ROMA testing.
Patient FAQ & Clinical Guidance
1. What does the ROMA test measure?
The ROMA test calculates ovarian malignancy probability by integrating CA125, HE4 blood levels with menopausal information. It provides a numerical score that classifies a woman as low or high risk for epithelial ovarian cancer, aiding in triage of pelvic masses. This dual‑marker approach outperforms CA125 alone, particularly in premenopausal patients.
2. Who should take the ROMA test?
Adnexal mass patients, both pre‑ and postmenopausal, should take the ROMA test for risk evaluation. It is recommended for any woman found to have a persistent ovarian cyst or complex mass on ultrasound, regardless of age, to guide referral to a gynecologic oncologist if needed.
3. How accurate is the ROMA test?
ROMA shows high sensitivity and specificity in detecting ovarian malignancy in pelvic mass patients. Clinical validation studies confirm its reliability as a non‑invasive stratification tool. Sensitivity is optimized in postmenopausal women, but the algorithm remains clinically informative across all menopausal statuses when used within the appropriate clinical context.
UAE Regulatory & Data Privacy Adherence
Our laboratory operations and data handling protocols strictly adhere to the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical governance and patient safety are ensured in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. All test results are delivered under strict confidentiality protocols.
Clinical & Logistical Metadata
| Test Name | ROMA (Risk of Ovarian Malignancy Algorithm) Score |
| Price (AED) | 750 AED |
| Turnaround Time | Same-day (sample collected Mon/Thu before 4 PM) |
| Sample Type / Matrix | Serum or Plasma |
| Methodology Used | Chemiluminescent Microparticle Immunoassay (CMIA) with Algorithmic Calculation |
| ICD-10-CM Code | R97.6 (Elevated tumor markers) |
| LOINC Code | 77399-3 (ROMA score) |
| DHA Facility License & Laboratory Address | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | License: 1143 |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians